TWEAKFn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells

Begoña Muñoz-Garca, Julio Madrigal-Matute, Juan A. Moreno, Jose L. Martin-Ventura, Oscar López-Franco, Cristina Sastre, Luis Ortega, Linda C. Burkly, Jesús Egido, Luis M. Blanco-Colio

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Aims Atherosclerotic plaque development can conclude with a thrombotic acute event triggered by plaque rupture/erosion. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumour necrosis factor superfamily that, through its receptor, fibroblast growth factor-inducible 14 (Fn14), participates in vascular remodelling, increasing vascular inflammatory responses and atherosclerotic lesion size in ApoE knockout mice. However, the role of the TWEAKFn14 axis in thrombosis has not been previously investigated.Methods and results We have examined whether TWEAK regulates expression of prothrombotic factors such as tissue factor (TF) and plasminogen activator inhibitor 1 (PAI-1) in atherosclerotic plaques as well as in human aortic vascular smooth muscle cells (hASMCs) in culture. Expression of TF and PAI-1 was colocalized and positively correlated with Fn14 in human carotid atherosclerotic plaques. In vitro, TWEAK increased TF and PAI-1 mRNA, protein expression and activity in hASMCs. All these effects were reversed using blocking anti-TWEAK monoclonal antibody, anti-Fn14 antibody or Fn14 small interfering RNA, indicating that TWEAK increased the prothrombotic state through its receptor, Fn14. Finally, ApoE-/- mice were fed a hyperlipidaemic diet for 10 weeks, then randomized and treated with saline (controls), TWEAK (10 g/kg/day), anti-TWEAK neutralizing monoclonal antibody (1000 g/kg/day), or non-specific immunoglobulin G (1000 g/kg/day) daily for 9 days. Systemic TWEAK injection increased TF and PAI-1 protein expression in the aortic root of ApoE-/- mice. Conversely, TWEAK blocking antibodies diminished both TF and PAI-1 protein expression compared with non-specific immunoglobulin G-treated mice. Conclusion sOur results indicate that the TWEAKFn14 axis can regulate activation of TF and PAI-1 expression in vascular cells. TWEAKFn14 may be a therapeutic target in the prothrombotic complications associated with atherosclerosis.

Original languageEnglish (US)
Pages (from-to)225-233
Number of pages9
JournalCardiovascular research
Volume89
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Plasminogen Activator Inhibitor 1
Thromboplastin
Tissue Plasminogen Activator
Atherosclerotic Plaques
Vascular Smooth Muscle
Smooth Muscle Myocytes
Apolipoproteins E
Replication Protein C
Blood Vessels
Tumor Necrosis Factor-alpha
Immunoglobulin G
Monoclonal Antibodies
Blocking Antibodies
Neutralizing Antibodies
Human Activities
Knockout Mice
Small Interfering RNA
Rupture
Atherosclerosis
Thrombosis

Keywords

  • Atherosclerosis
  • Coagulation
  • Plasminogen activator inhibitor 1
  • Tissue factor
  • TWEAK

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

TWEAKFn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. / Muñoz-Garca, Begoña; Madrigal-Matute, Julio; Moreno, Juan A.; Martin-Ventura, Jose L.; López-Franco, Oscar; Sastre, Cristina; Ortega, Luis; Burkly, Linda C.; Egido, Jesús; Blanco-Colio, Luis M.

In: Cardiovascular research, Vol. 89, No. 1, 01.01.2011, p. 225-233.

Research output: Contribution to journalArticle

Muñoz-Garca, B, Madrigal-Matute, J, Moreno, JA, Martin-Ventura, JL, López-Franco, O, Sastre, C, Ortega, L, Burkly, LC, Egido, J & Blanco-Colio, LM 2011, 'TWEAKFn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells', Cardiovascular research, vol. 89, no. 1, pp. 225-233. https://doi.org/10.1093/cvr/cvq278
Muñoz-Garca, Begoña ; Madrigal-Matute, Julio ; Moreno, Juan A. ; Martin-Ventura, Jose L. ; López-Franco, Oscar ; Sastre, Cristina ; Ortega, Luis ; Burkly, Linda C. ; Egido, Jesús ; Blanco-Colio, Luis M. / TWEAKFn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. In: Cardiovascular research. 2011 ; Vol. 89, No. 1. pp. 225-233.
@article{e2d1117d535a405998521713cf6e9314,
title = "TWEAKFn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells",
abstract = "Aims Atherosclerotic plaque development can conclude with a thrombotic acute event triggered by plaque rupture/erosion. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumour necrosis factor superfamily that, through its receptor, fibroblast growth factor-inducible 14 (Fn14), participates in vascular remodelling, increasing vascular inflammatory responses and atherosclerotic lesion size in ApoE knockout mice. However, the role of the TWEAKFn14 axis in thrombosis has not been previously investigated.Methods and results We have examined whether TWEAK regulates expression of prothrombotic factors such as tissue factor (TF) and plasminogen activator inhibitor 1 (PAI-1) in atherosclerotic plaques as well as in human aortic vascular smooth muscle cells (hASMCs) in culture. Expression of TF and PAI-1 was colocalized and positively correlated with Fn14 in human carotid atherosclerotic plaques. In vitro, TWEAK increased TF and PAI-1 mRNA, protein expression and activity in hASMCs. All these effects were reversed using blocking anti-TWEAK monoclonal antibody, anti-Fn14 antibody or Fn14 small interfering RNA, indicating that TWEAK increased the prothrombotic state through its receptor, Fn14. Finally, ApoE-/- mice were fed a hyperlipidaemic diet for 10 weeks, then randomized and treated with saline (controls), TWEAK (10 g/kg/day), anti-TWEAK neutralizing monoclonal antibody (1000 g/kg/day), or non-specific immunoglobulin G (1000 g/kg/day) daily for 9 days. Systemic TWEAK injection increased TF and PAI-1 protein expression in the aortic root of ApoE-/- mice. Conversely, TWEAK blocking antibodies diminished both TF and PAI-1 protein expression compared with non-specific immunoglobulin G-treated mice. Conclusion sOur results indicate that the TWEAKFn14 axis can regulate activation of TF and PAI-1 expression in vascular cells. TWEAKFn14 may be a therapeutic target in the prothrombotic complications associated with atherosclerosis.",
keywords = "Atherosclerosis, Coagulation, Plasminogen activator inhibitor 1, Tissue factor, TWEAK",
author = "Bego{\~n}a Mu{\~n}oz-Garca and Julio Madrigal-Matute and Moreno, {Juan A.} and Martin-Ventura, {Jose L.} and Oscar L{\'o}pez-Franco and Cristina Sastre and Luis Ortega and Burkly, {Linda C.} and Jes{\'u}s Egido and Blanco-Colio, {Luis M.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1093/cvr/cvq278",
language = "English (US)",
volume = "89",
pages = "225--233",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - TWEAKFn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells

AU - Muñoz-Garca, Begoña

AU - Madrigal-Matute, Julio

AU - Moreno, Juan A.

AU - Martin-Ventura, Jose L.

AU - López-Franco, Oscar

AU - Sastre, Cristina

AU - Ortega, Luis

AU - Burkly, Linda C.

AU - Egido, Jesús

AU - Blanco-Colio, Luis M.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Aims Atherosclerotic plaque development can conclude with a thrombotic acute event triggered by plaque rupture/erosion. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumour necrosis factor superfamily that, through its receptor, fibroblast growth factor-inducible 14 (Fn14), participates in vascular remodelling, increasing vascular inflammatory responses and atherosclerotic lesion size in ApoE knockout mice. However, the role of the TWEAKFn14 axis in thrombosis has not been previously investigated.Methods and results We have examined whether TWEAK regulates expression of prothrombotic factors such as tissue factor (TF) and plasminogen activator inhibitor 1 (PAI-1) in atherosclerotic plaques as well as in human aortic vascular smooth muscle cells (hASMCs) in culture. Expression of TF and PAI-1 was colocalized and positively correlated with Fn14 in human carotid atherosclerotic plaques. In vitro, TWEAK increased TF and PAI-1 mRNA, protein expression and activity in hASMCs. All these effects were reversed using blocking anti-TWEAK monoclonal antibody, anti-Fn14 antibody or Fn14 small interfering RNA, indicating that TWEAK increased the prothrombotic state through its receptor, Fn14. Finally, ApoE-/- mice were fed a hyperlipidaemic diet for 10 weeks, then randomized and treated with saline (controls), TWEAK (10 g/kg/day), anti-TWEAK neutralizing monoclonal antibody (1000 g/kg/day), or non-specific immunoglobulin G (1000 g/kg/day) daily for 9 days. Systemic TWEAK injection increased TF and PAI-1 protein expression in the aortic root of ApoE-/- mice. Conversely, TWEAK blocking antibodies diminished both TF and PAI-1 protein expression compared with non-specific immunoglobulin G-treated mice. Conclusion sOur results indicate that the TWEAKFn14 axis can regulate activation of TF and PAI-1 expression in vascular cells. TWEAKFn14 may be a therapeutic target in the prothrombotic complications associated with atherosclerosis.

AB - Aims Atherosclerotic plaque development can conclude with a thrombotic acute event triggered by plaque rupture/erosion. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumour necrosis factor superfamily that, through its receptor, fibroblast growth factor-inducible 14 (Fn14), participates in vascular remodelling, increasing vascular inflammatory responses and atherosclerotic lesion size in ApoE knockout mice. However, the role of the TWEAKFn14 axis in thrombosis has not been previously investigated.Methods and results We have examined whether TWEAK regulates expression of prothrombotic factors such as tissue factor (TF) and plasminogen activator inhibitor 1 (PAI-1) in atherosclerotic plaques as well as in human aortic vascular smooth muscle cells (hASMCs) in culture. Expression of TF and PAI-1 was colocalized and positively correlated with Fn14 in human carotid atherosclerotic plaques. In vitro, TWEAK increased TF and PAI-1 mRNA, protein expression and activity in hASMCs. All these effects were reversed using blocking anti-TWEAK monoclonal antibody, anti-Fn14 antibody or Fn14 small interfering RNA, indicating that TWEAK increased the prothrombotic state through its receptor, Fn14. Finally, ApoE-/- mice were fed a hyperlipidaemic diet for 10 weeks, then randomized and treated with saline (controls), TWEAK (10 g/kg/day), anti-TWEAK neutralizing monoclonal antibody (1000 g/kg/day), or non-specific immunoglobulin G (1000 g/kg/day) daily for 9 days. Systemic TWEAK injection increased TF and PAI-1 protein expression in the aortic root of ApoE-/- mice. Conversely, TWEAK blocking antibodies diminished both TF and PAI-1 protein expression compared with non-specific immunoglobulin G-treated mice. Conclusion sOur results indicate that the TWEAKFn14 axis can regulate activation of TF and PAI-1 expression in vascular cells. TWEAKFn14 may be a therapeutic target in the prothrombotic complications associated with atherosclerosis.

KW - Atherosclerosis

KW - Coagulation

KW - Plasminogen activator inhibitor 1

KW - Tissue factor

KW - TWEAK

UR - http://www.scopus.com/inward/record.url?scp=78650467139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650467139&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvq278

DO - 10.1093/cvr/cvq278

M3 - Article

C2 - 20810696

AN - SCOPUS:78650467139

VL - 89

SP - 225

EP - 233

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -